Biotech Perspectives: Startup to Acquisition featuring Stig Hansen & Jay Shepard
We are VERY excited to announce our next BALT speaker event starring Bay Area biotech CEOs Stig Hansen and Jay Shepard in a fireside chat format! Stig will be approaching the discussion from a very successful startup perspective and Jay will provide insights into how you make a $700 million dollars (US) to Pfizer happen. It should make for an awesome experience and we hope you will join us to provide the usual BALT energy at this event!
Beer, wine, awesome appetizers and a beautiful venue will be provided by our fantastic event host, the international law firm DLA Piper!
To cover our costs, we are asking for $15 from the early birds and $20 for the late bird RSVP's. So, register ASAP! Thank you and hope to see you on May 23!! Best, Luke
Agenda - 5:30-6:30 Networking, 6:30-7:45 Intros and Showtime, 7:45-9:00 Networking
Our featured speakers:
Stig Hansen, PhD CEO & Co-Founder Carmot Therapeutics
Dr. Stig K. Hansen is co-founder and CEO of Carmot Therapeutics, which is discovering novel therapeutics for major human diseases. Carmot’s proprietary platform, Chemotype Evolution, provides access to novel chemical diversity with the opportunity to tackle challenging, high-value targets that are inaccessible to current technologies. Dr. Hansen is a co-inventor of Chemotype Evolution and founded Carmot to commercialize the technology. Carmot is a VC backed company and has received multiple grants from private foundations and federal agencies.
Dr. Hansen holds an MS in biochemistry and a PhD in molecular and cell biology from the University of Copenhagen, Denmark. Dr. Hansen conducted his PhD studies in the laboratory of Dr. Robert Tjian at UC Berkeley, where he made seminal discoveries in the field of transcriptional regulation. Dr. Hansen was a Novartis Fellow of the Life Sciences Research Foundation in the laboratory of Dr. Tito Serafini, UC Berkeley, where he studied mammalian brain development. In 2000, Dr. Hansen joined Sunesis Pharmaceuticals, where he was instrumental in applying Sunesis technology in the drug discovery process. During his 8 years at Sunesis, Dr. Hansen advanced to associate director of biology and led programs in metabolic disease, auto-immunity, and oncology, with two programs advancing into clinical development. Dr. Hansen also served on the Research Operations Committee overseeing all research from project initiation through Phase II and managed research partnerships with Johnson & Johnson and Biogen Idec.
Jay Shepard CEO NextWave Pharmaceuticals (now Pfizer)
Most recently, Jay was President and CEO of NextWave Pharmaceuticals which was acquired by Pfizer in November 2012 in a deal worth up to $700 million. He has more than 25 years’ experience in the pharmaceutical, biotechnology and drug delivery arenas. In addition to his responsibilities as CEO to NextWave Pharmaceuticals Jay maintains a strategic advisor relationship with Sofinnova Ventures (NextWave Pharmaceuticals is a Sofinnova portfolio company). Jay joined Sofinnova in 2008, as an Executive in Residence.
Prior to Sofinnova Ventures, Jay was President and CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen for $420 million. He then helped with Ilypsa's spin-out of Relypsa, serving as interim President and CEO. Before Ilypsa, Jay served as Vice President, Commercial Operations at Telik, where he was responsible for all activities relating to market preparation toward the launch of the company's lead oncology compounds. He was also Vice President of ALZA Pharmaceuticals' Oncology Business Unit, having held leadership positions of increasing responsibility in the establishment and operation of ALZA's specialty pharmaceutical sales and marketing group. Jay began his career in pharmaceutical sales and marketing at Ortho Pharmaceutical and Syntex Laboratories. Jay holds a B.S. in Business Administration from the University of Arizona.